Technical Data
Troponin I, Cardiac, Human (cTnI, TNNC1) BioAssay™ ELISA Kit
Kits and Assays Storage: 4°CShipping: Blue Ice
Intended Use:
Troponin I, Human, BioAssay™ ELISA Kit is intended for the quantitative determination of cardiac troponin I in human serum. Measurement of troponin I values are useful in the research of acute myocardial infarction (AMI).

Troponin is the inhibitory or contractile regulating protein complex of striated muscle. It is located periodically along the thin filament of the muscle and consists of three distinct proteins; troponin I, troponin C, and troponin T.1-5 Likewise, the troponin I subunit exists in three separate isoforms; two in fast-twitch and slow-twitch skeletal muscle fibers, and one in cardiac muscle. The cardiac isoform (cTnI) is about 40% dissimilar, has a molecular weight of 22,500 daltons, and has 31 additional amino acid residues that are not present on the skeletal isoforms. Antibodies made against this cardiac isoform are immunologically different from antibodies made against the other two skeletal isoforms, and the unique isoform and tissue specificity of cardiac troponin I is the basis for its use as an aid in the diagnosis of acute myocardial infarction.

The most recently described and preferred biomarker for myocardial damage is cardiac troponin (I or T). The cardiac troponins exhibit myocardial tissue specificity and high sensitivity. Likewise, cardiac TnI and CK-MB have similar release patterns (4-6 hours after the onset of pain), but the level of cTnI remains elevated for a much longer period of time (6-10 days), thus providing for a longer window of detection of cardiac injury.

Normal levels of cTn I in the blood are very low. After the onset of an AMI, cTnI levels increase substantially and are measurable in serum within 4 to 6 hours, with peak concentrations reached in approximately 12 to 24 hours after infarction. The fact that cTnI remains elevated in serum for a much longer period of time, added to its enhanced diagnostic sensitivity and cardiac specificity, allows for the detection of AMI much earlier after the onset of ischemia (4 hours), as well as the diagnosis of peri-operative infarction in situations where a high serum level of skeletal muscle proteins are expected.

Additionally, recent data have identified a measurable relationship between cardiac troponin levels and long-term outcome after an episode of chest discomfort. The studies suggest that the use of the cTnI demonstrates high predictive value in delineating the high risk group of unstable angina patients, and that these tests may be particularly useful in evaluating patient condition prior to discharge from the ED.

The United States Biological Troponin I, Human, BioAssay™ ELISA Kit provides a rapid, sensitive, and reliable assay for the quantitative measurement of cardiac-specific troponin I. The antibodies developed for the test will determine a minimal concentration of 1ng/ml, and there is no cross-reactivity with human cardiac troponin T or skeletal troponin T or I.

Kit Components:
T8665-15S1: Microtiter Plate: 1x96 wells
T8665-15S2: TnI Standard, 75ng/ml: 1x1vial
T8665-15S3: TnI Standard, 30ng/ml: 1x1vial
T8665-15S4: TnI Standard, 7.5ng/ml: 1x1vial
T8665-15S5: TnI Standard, 2.0ng/ml: 1x1vial
T8665-15S6: TnI Standard, 0ng/ml: 1x1vial
T8665-15S7: Tnl (HRP) mouse x human: 1x13ml
T8665-15S8: Tetramethylbenzidine (TMB): 1x11ml
T8665-15S9: Stop Solution: 1x11ml (1N HCl)

Storage and Stability:
Store all components at 4°C. Reconstitute Standards (T8665-15S2-T8665-15S6) with 1ml ddH2O (20min, RT). Aliquot and store at -20°C. Kit contents are Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Adams, J. et, al., N. Eng. J. Med., 330: 670-4, 1994. 2. Meyer, et. al., Cardiology, 90:286-94, 1998. 3. Polanczyk, C.A., et al., J. Am. Coll. Cardiol., 32:8-14, 1998. 4. D'Costa, et al., Am. J. Clin. Pathol., 108:550-5, 1997. 5. Rice, M.S., et al., J. Am. Board Fam. Pract., 12:214-8, 1999. 6. Hamm, C.W., et al., N. Engl. J. Med., 337:1648-53, 1997. 7. Joint European Society of Cardiology/American College of Cardiology: J. Am. Coll. Cardio., 36: 3, (2000). 8. Cummins, B., et. al., Am. Heart J., 113:1333, 1987. 10. Ebell, M.H., et al., J. Fam. Pract., 49: 746-53, 2000. 11. Mair, J., et. al.:. Clin. Chem., 41: 1266-72, 1995. 12. Bertinchant, J.P., et al., Clin. Bio. Chem., 29: 587-94, 1996. 13. Bodor, G.S, J. Clin. Immunoassay, 17: 40-4, 1994. 14. Antman, E.M., et al., N. Engl. J. Med., 335:1342-9, 1996. 15. Ellestad, M.H., A Symposium Sponsored by Baylor College of Medicine, held during the 68th Scientific Session of the American Heart Association, November 11, 1995, Anaheim, California. 16. Hanfner, S., et. al.: Cardiac troponins in serum in chronic renal failure. Clin. Chem., 40:1790 1994. 17. U.S. Department of Labor, Occupational Safety and Health Administration, 29 CFR Part 1910.1030. Occupational Exposure ot Bloodborne Pathogens; Final Rule. Federal Register; 56(235):64175, 1991. 18. USA Center for Disease Control/National Institute of Health Manual, “Biosafety in Microbiological and Biomedical Laboratories”, (1984).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.